CLL with TP53 or del17p findings: questions before treatment selection

In CLL, TP53 or del17p findings can influence treatment selection, but they do not automatically mean that treatment must start immediately. The first conversation should separate two questions: is there a clinical reason to begin therapy now, and how do the genetic findings affect the options if treatment is needed?

TP53 and del17p are related findings, not identical tests

Del17p describes a deletion involving part of chromosome 17, while TP53 testing looks for changes in the gene. A FISH result and a gene-variant report therefore answer different laboratory questions. Keep both complete reports where available; a negative result for one should not be rewritten as proof that the other was tested and negative too.

Ask the haematologist which tests were performed and whether their dates are appropriate for the decision now being considered. If only a summary saying “high risk” is available, request the underlying result. The clinician needs the actual finding, not a risk label copied from an earlier consultation.

Do not turn a risk marker into a personal deadline

Some people with CLL remain under observation despite adverse prognostic findings when there is no indication to treat. When therapy is required, TP53 disruption can be important in choosing an approach. Those two statements are compatible: a marker can matter greatly for treatment selection without independently determining the day treatment begins.

If the current recommendation is observation, ask what is being monitored and which changes would prompt reassessment. If treatment is proposed, ask what has changed clinically. This gives the patient a concrete explanation of timing instead of a sense that any delay contradicts the laboratory report.

Compare the plan, not just the medicine name

Ask how the proposed option addresses the disease findings and how other illnesses, prior therapies and current medicines were considered. A second opinion should have the same information. Send the actual prescription list and reasons previous treatment was stopped, especially where adverse effects or an interaction affected the decision.

Practical differences also matter to an informed discussion. Is the proposed course intended for a defined period, or is continuing treatment part of the plan? What monitoring is required when it begins? Which visits need the specialist centre, and which can be arranged near home? The treating team should answer for the particular regimen rather than describe all CLL therapies as one package.

Read older risk information in its clinical context

Families may find survival figures attached to TP53 or del17p in older articles. Ask the specialist whether that information reflects comparable treatment and patients before applying it to the present situation. A laboratory finding does not provide an individual’s survival estimate or make every advertised new treatment appropriate.

If a clinical trial is being considered, obtain the actual study information and clarify the eligibility assessment. The distinction between an enquiry and acceptance matters, as does the alternative plan if participation is not possible. No travel or treatment interruption should depend solely on a promotional description of access.

For haematology assessment in Turkey, put the current clinical decision and original genetic reports first. Ask for a written explanation of whether the reviewer agrees with treatment timing and, separately, with the proposed regimen. Include the plan for prescriptions and follow-up if care will be shared between countries.

The useful outcome is a decision linked to the person’s current disease and circumstances. It should explain what is settled, what remains to be checked and who will review the next result, while keeping the established treating team involved.

Sources

• NCI: Chronic Lymphocytic Leukemia Treatment